Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | HTT | P42858 | 2/20 | 1.00 |
| ▸ | ESR1 | P03372 | 1/20 | 0.81 |
| ▸ | SHBG | P04278 | 1/20 | 0.81 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.81 |
| ▸ | MAPT | P10636 | 5/20 | 0.71 |
| ▸ | RAB9A | P51151 | 4/20 | 0.71 |
| ▸ | NPC1 | O15118 | 3/20 | 0.71 |
| ▸ | GAA | P10253 | 2/20 | 0.71 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.66 |
| ▸ | HPGD | P15428 | 2/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | ATM | Q13315 | 1/20 | 0.66 |
| ▸ | TP53 | P04637 | 3/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL312243 | 0.90 | ESR1 (1.00) | LMNASMN1; SMN2HTTESR1SHBG | |
| SCHEMBL30503014 | 0.90 | ESR1 (1.00) | LMNASMN1; SMN2HTTESR1SHBG | |
| SCHEMBL22925087 | 0.87 | LMNA (0.77) | LMNASMN1; SMN2HTTESR1SHBG | |
| SCHEMBL29574422 | 0.87 | LMNA (0.77) | LMNASMN1; SMN2HTTESR1SHBG | |
| SCHEMBL16322177 | 0.87 | LMNA (0.77) | LMNASMN1; SMN2HTTESR1SHBG | |
| SCHEMBL17637167 | 0.84 | LMNA (0.72) | LMNASMN1; SMN2HTTESR1SHBG | |
| SCHEMBL2331741 | 0.83 | LMNA (1.00) | LMNASMN1; SMN2HTTESR1SHBG | |
| SCHEMBL38652384 | 0.83 | ESR1 (0.81) | LMNASMN1; SMN2HTTESR1SHBG | |
| SCHEMBL22672221 | 0.83 | ESR1 (0.81) | LMNASMN1; SMN2HTTESR1SHBG | |
| SCHEMBL3586687 | 0.83 | ESR1 (0.81) | LMNASMN1; SMN2HTTESR1SHBG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3010502-B1 | AZETIDINE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | SERAGON PHARMACEUTICALS INC (US) | 2018-11-21 | — | — | EP | disclosed |
| US-20170362210-A1 | ANTI-ESTROGENIC COMPOUNDS | PFIZER INC. (US) | 2017-12-21 | — | — | US | disclosed |
| US-9655880-B2 | Azetidine estrogen receptor modulators and uses thereof | GENENTECH, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-9655880-B2 | Azetidine estrogen receptor modulators and uses thereof | GENENTECH, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-9655880-B2 | Azetidine estrogen receptor modulators and uses thereof | GENENTECH, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-20160367526-A1 | AZETIDINE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-12-22 | — | — | US | disclosed |
| US-20160367526-A1 | AZETIDINE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-12-22 | — | — | US | disclosed |
| US-20160367526-A1 | AZETIDINE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-12-22 | — | — | US | disclosed |
| WO-2016174551-A1 | ANTI-ESTROGENIC COMPOUNDS | PFIZER INC. (US) | 2016-11-03 | — | — | WO | disclosed |
| US-20160311805-A1 | ANTI-ESTROGENIC COMPOUNDS | PFIZER INC. (US) | 2016-10-27 | — | — | US | disclosed |
| EP-3010502-A1 | AZETIDINE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | Seragon Pharmaceuticals, Inc. (US) | 2016-04-27 | — | — | EP | disclosed |
| US-20160090377-A1 | AZETIDINE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-03-31 | — | — | US | disclosed |
| US-20160090377-A1 | AZETIDINE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-03-31 | — | — | US | disclosed |
| US-20160090377-A1 | AZETIDINE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-03-31 | — | — | US | disclosed |
| WO-2014205136-A1 | AZETIDINE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | SERAGON PHARMACEUTICALS, INC. (US) | 2014-12-24 | — | — | WO | disclosed |
| WO-2014205136-A1 | AZETIDINE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | SERAGON PHARMACEUTICALS, INC. (US) | 2014-12-24 | — | — | WO | disclosed |
| WO-2009026657-A1 | FLAVONOID PPAR AGONISTS | THE UNIVERSITY OF SYDNEY (AU) | 2009-03-05 | — | — | WO | disclosed |
| WO-2009026658-A1 | PPAR AGONISTS | THE UNIVERSITY OF SYDNEY (AU) | 2009-03-05 | — | — | WO | disclosed |
| WO-2009026657-A1 | FLAVONOID PPAR AGONISTS | THE UNIVERSITY OF SYDNEY (AU) | 2009-03-05 | — | — | WO | disclosed |
| WO-2009026658-A1 | PPAR AGONISTS | THE UNIVERSITY OF SYDNEY (AU) | 2009-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160090377-A1 | AZETIDINE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR1, ESR2, GPER1 | LMNA 4219/4885SMN1; SMN2 4543/4885HTT 2825/4885 |
| US-20160367526-A1 | AZETIDINE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR1, ESR2, GPER1 | LMNA 4219/4885SMN1; SMN2 4543/4885HTT 2825/4885 |
| US-20170362210-A1 | ANTI-ESTROGENIC COMPOUNDS | ESR1, ESRRA, ESR2 | LMNA 1522/4885SMN1; SMN2 2796/4885HTT 3174/4885 |
| US-20160311805-A1 | ANTI-ESTROGENIC COMPOUNDS | ESR1, ESRRA, ESR2 | LMNA 1522/4885SMN1; SMN2 2796/4885HTT 3174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.